← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Fibrogen, Inc.
South San Francisco, CA
$2,055,487
Total funding
6
Grants
Funding over time
peak $497.2K · FY2006–07$500K$375K$250K$125K$0
'06
'07
Funding mix
By agency
NIH$1,955,487 · 5
NSF$100,000 · 1
By mechanism
R01$864,000 · 1
R44$793,135 · 1
R43$298,352 · 3
—$100,000 · 1
Investigators at Fibrogen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
HbF Induction by Prolyl Hydroxylase Inhibitors in Non-human Primates$497,166
R44 · FY2007 · HL
HbF Induction by Prolyl Hydroxylase Inhibitors$295,969
R44 · FY2006 · HL
RECOMBINANT HUMAN COLLAGEN &CTGF FOR TISSUE ENGINEERING$288,000
R01 · FY2000 · AR
RECOMBINANT HUMAN COLLAGEN &CTGF FOR TISSUE ENGINEERING$288,000
R01 · FY2001 · AR
RECOMBINANT HUMAN COLLAGEN &CTGF FOR TISSUE ENGINEERING$288,000
R01 · FY2002 · AR
DEVELOPMENT OF A TOPICAL ANTI-SCARRING AGENT$110,852
R43 · FY2001 · GM
STTR Phase I: Production and Characterization of Recombinant Gelatin in Transgenic Rice Cell Cultures$100,000
· FY2004 · TIP
Development of CTGF antibodies that block angiogenesis$100,000
R43 · FY2003 · CA
Induction of HbF by Prolyl Hydroxylase Inhibitors$87,500
R43 · FY2004 · HL